We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+1.77%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$6.85B
AUM Growth
+$217M
Cap. Flow
+$578M
Cap. Flow %
8.44%
Top 10 Hldgs %
38.32%
Holding
136
New
16
Increased
27
Reduced
15
Closed
11

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$112M
2
APLS
Apellis Pharmaceuticals
APLS
+$78.4M
3
PEN icon
Penumbra
PEN
+$62.3M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$54.4M
5
ARGX icon
argenx
ARGX
+$53.9M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$153M
2
INMD icon
InMode
INMD
+$19.9M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$17.3M
4
AGEN
Agenus
AGEN
+$12.9M
5
GH icon
Guardant Health
GH
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.33%
2 Financials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OM icon
51
Outset Medical
OM
$90.8M
$41.2M 0.6%
59,643
– –
OYST
52
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$37.6M 0.55%
2,058,504
+197,295
+11% +$2.5M
EPIX
53
DELISTED
ESSA Pharma
EPIX
$37.4M 0.55%
2,637,192
– –
LUNG icon
54
Pulmonx
LUNG
$87.6M
$37.3M 0.55%
1,164,600
– –
VTYX
55
DELISTED
Ventyx Biosciences
VTYX
$30.8M 0.45%
+1,551,778
New +$29.4M
QTRX icon
56
Quanterix
QTRX
$190M
$29.1M 0.43%
+686,470
New +$32.1M
MIST icon
57
Milestone Pharmaceuticals
MIST
$152M
$28.3M 0.41%
4,315,102
– –
CTMX icon
58
CytomX Therapeutics
CTMX
$754M
$26.1M 0.38%
6,029,700
+4,628,761
+330% +$27.1M
CSTL icon
59
Castle Biosciences
CSTL
$979M
$25.7M 0.38%
599,009
– –
NSTG
60
DELISTED
NanoString Technologies, Inc.
NSTG
$25.5M 0.37%
604,029
-200,000
-25% -$8.75M
LONA
61
LeonaBio Inc
LONA
$72.1M
$24.8M 0.36%
190,656
– –
GLUE icon
62
Monte Rosa Therapeutics
GLUE
$1.35B
$24.8M 0.36%
1,214,572
– –
JNCE
63
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$23.9M 0.35%
2,863,198
+1,466,995
+105% +$12.1M
PYXS icon
64
Pyxis Oncology
PYXS
$236M
$23.3M 0.34%
+2,120,760
New +$24.3M
ARWR icon
65
Arrowhead Research
ARWR
$12.4B
$23M 0.34%
+346,842
New +$23.8M
CERE
66
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$21.6M 0.32%
666,666
– –
JNJ icon
67
Johnson & Johnson
JNJ
$625B
$21.4M 0.31%
125,127
-45,415
-27% -$7.44M
SGHT icon
68
Sight Sciences
SGHT
$412M
$20.8M 0.3%
1,183,871
-100,000
-8% -$2.19M
LABP
69
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
$20.5M 0.3%
427,572
– –
RCOR
70
DELISTED
Renovacor, Inc.
RCOR
$20.4M 0.3%
2,647,540
+460,000
+21% +$3.8M
AGEN
71
Agenus
AGEN
$290M
$18.9M 0.28%
298,991
-163,352
-35% -$12.9M
OLK
72
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$18.5M 0.27%
1,018,188
-300,000
-23% -$7.4M
WHWK
73
Whitehawk Therapeutics
WHWK
$271M
$18.5M 0.27%
764,701
– –
TELA icon
74
TELA Bio
TELA
$38.9M
$17.9M 0.26%
1,399,686
+8,067
+0.6% +$102K
IMUX icon
75
Immunic
IMUX
$195M
$16.4M 0.24%
171,547
+34,466
+25% +$3.1M
1 2
3
4 5

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

RTW Investments's Q4 2021 Portfolio in Review

As of Q4 2021, RTW Investments held 136 positions worth $6.85B, up 3.3% from $6.63B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

RTW Investments deployed $578M of net new capital in Q4 2021, opening 16 new positions and adding to 27 existing holdings. Its largest new stake was Ultragenyx Pharmaceutical: 1,373,284 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was IDEAYA Biosciences, an estimated $17.3M trimmed.

  • RTW Investments's largest Q4 2021 buy was Ultragenyx Pharmaceutical: 1,373,284 shares worth $115M.
  • RTW Investments added most to Penumbra in Q4 2021, an estimated $62.3M increase.
  • RTW Investments's biggest Q4 2021 reduction was IDEAYA Biosciences, cutting an estimated $17.3M.
  • RTW Investments fully exited Dicerna Pharmaceuticals, Inc. in Q4 2021, selling an estimated $153M.
  • RTW Investments's ten largest holdings make up 38% of its $6.85B portfolio in Q4 2021.
  • RTW Investments opened 16 new positions and closed 11 in Q4 2021.
  • RTW Investments's portfolio value rose 3.3% quarter-over-quarter to $6.85B.

Based on RTW Investments's 13F filing for Q4 2021, filed 14 Feb 2022.